UK research consortium given £2 million to control monkeypox
£2 million will help fund a UK team of scientific experts to research monkeypox, uncover novel treatments and curb the spread of the virus.
List view / Grid view
News
Steep drop for UK industry clinical trials between 2017 and 2021
COVID-19 has accelerated the decline in late-stage industry clinical research in the UK, compared to its global peers.
Three-dose vaccine prevents HIV patients getting hepatitis B
Clinical trial results suggest adult HIV patients can be protected against hepatitis B with a three-dose vaccine series.
Gilead and MacroGenics to develop bispecific cancer antibodies
A collaboration agreement between Gilead and biopharma company MacroGenics aims to develop MGD024, a bispecific antibody for treatment of blood cancers.
Shingles vaccine offers a decade of protection in older adults
Shingrix can effectively vaccinate adults over 50 years old against shingles for at least 10 years, new data shows.
First patient receives novel, potentially cancer-stopping pill
City of Hope has developed AOH1996, a promising cancer medicine, for people with reoccurring solid tumours.
Immunotherapy shows benefits for hospitalised COVID-19 patients
Apogenix’s asunercept demonstrates efficacy in Phase II trial for the treatment of hospitalised COVID-19 patients.
Full data set for new buffer stock blending system freely available
NIIMBL and BioPhorum reveal open-access design models for a new buffer stock blending system that could help reduce bottlenecks in biomanufacturing plants.
First oral combined estetrol contraceptive available in UK
The first oral contraceptive tablet using a combination of estetrol (E4) and drospirenone (DRSP) is available in the UK.
Lilly will acquire Akouos to accelerate hearing loss therapies
Eli Lilly and Company’s $610 million acquisition of Akouos will fast-track gene therapies that restore, improve and preserve hearing for patients worldwide.
$38 million will fund rare disease research over four-year period
Research for rare diseases including ALS will be supported over the next four years by $38 million in FDA funding.
Evaluating benefits of outsourcing biopharma R&D
Near-term gains from outsourcing biopharma R&D activities can be offset by slower innovation in the long run, according to a recent paper.
EC approves CAR T-Cell therapy for B-cell lymphoma
Yescarta approved by EC for the treatment of large B-Cell lypmphoma and high grade B-cell lymphoma.
£12 million given to Sheffield Biomedical Research Centre
The UK’s Sheffield Biomedical Research Centre has been awarded £12 million to help accelerate R&D of vaccines and treat conditions like HIV.
HPAPI contract manufacturing to value $14.6 billion by 2030
Rising demand for cancer drugs, combined with high in-house manufacturing costs is driving growth in the high-potency API outsourcing market.
